Stock INKT MINK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Delayed Nasdaq
Other stock markets
 12:06:26 2024-06-03 pm EDT 		5-day change 1st Jan Change
0.95 USD -2.06% Intraday chart for MiNK Therapeutics, Inc. +1.06% -11.21%
May. 22 MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting CI
May. 14 Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
MiNK Reports First Quarter 2024 Results
MiNK Reports First Quarter 2024 Results
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
MiNK Reports Fourth Quarter and Year-End 2023 Results
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INKT Stock
  4. News MiNK Therapeutics, Inc.
  5. Other languages